Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

House Democrats Hope To Forge Deal On Package, Wait For Score
As they worked to move health care reform legislation through the Energy and Commerce Committee, House Democrats said they were close to a compromise with fiscally conservative Democrats, a group that so far has been a roadblock, The Hill reports.
generic viagra online
High-Cost Medicare Areas Worry About Looming Cuts
The White House"s pressure to cut soaring healthcare costs is causing action and concern in high cost Medicare areas, especially South Florida.
News of the day
Extracorporeal Shock Wave Therapy For The Treatment Of Chronic Pelvic Pain Syndrome In Males: A Randomised, Double-Blind, Placebo-Controlled Study
UroToday.com - At a glance one could assume that this study was solely empirical - on the contrary! Shock waves (SWs) seem to have a greater therapeutic potential than is assumed and understood today. Finally, the effect of SW cannot be explained by current models of thinking. The recently published SW model by Wess1 is a very promising and tremendous basic approach: SW could modify brain processes and pain storage patterns - both to be influenced therapeutically. We are going to follow these concepts by specific research investigating processes inside the brain during SW application. Possible reactions in the brain and changes under running Extracorporeal Shock Wave Treatment (ESWT) are presently the most promising approaches to understanding the working mechanisms of SW. We intend to apply SWs not only clinically, but also to enhance our knowledge by basic research about their therapeutic effects. The missing animal model for chronic pelvic pain syndrome (CPPS) does not contribute to simplifying the understanding of pathophysiological processes influenced by ESWT, in particular due to the fact that the knowledge about CPPS pathophysiology itself is very limited.
Medical Devices

PPD Confirms Takeda Receives FDA Complete Response For Alogliptin

PPD, Inc. (NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin. PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin. PPD announced on March 6, 2009, that the FDA had informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA guidance. PPD


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009